
Aclarion Inc (ACON) Stock Forecast & Price Target
Aclarion Inc (ACON) Analyst Ratings
Bulls say
Aclarion is a healthcare technology company with a positive outlook, driven by recent commercial agreements with Weill Cornell Medicine and Och Spine, as well as the appointment of a Commercial Director, Western US. Despite relatively nominal revenues in Q4 FY25, the company saw an 81% increase in revenue Yoy and rising Nociscan scan volume, with an expected CLARITY trial data readout in Q3 2026. With a strong balance sheet and potential for significant market opportunity, Aclarion's stock has potential for growth, despite the risks of balance sheet/liquidity, regulatory approvals, and competition.
Bears say
Aclarion is facing difficulties with share count expansion, with a significant increase to 2.3 million shares from 670 thousand last quarter. This has resulted in a decrease in the 12-month price target to $7.00 (from $23.00). Despite this, the company's net cash per share is currently sitting at $17 and the commercialization of Nociscan is expected to bring in significant revenue, although slower adoption from surgeons and higher expenses could present risks to the overall thesis.
This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.
Aclarion Inc (ACON) Analyst Forecast & Price Prediction
Start investing in Aclarion Inc (ACON)
Order type
Buy in
Order amount
Est. shares
0 shares